Method of treating fatty liver diseases and conditions in non-lipodystrophic subjects
The invention generally relates to the use of leptin in the treatment of a leptin-responsive disease or condition in a non-lipodystrophic subject. More particularly, the invention is directed to the use of leptin in the treatment of a fatty liver disease in a non-lipodystrophic subject with a relative leptin deficiency. The invention includes methods for the treatment of nonalcoholic steatohepatitis (NASH), alcoholic fatty liver disease (AFLD), and nonalcoholic fatty liver disease (NAFLD) in a non-lipodystrophic subject. The invention includes the treatment of conditions ranging from ectopic lipid accumulation (steatosis) to cirrhosis.
1. A method of treating a fatty liver condition in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to treat the condition in the subject.
2. The method of claim 1 , wherein the subject has a relative leptin deficiency.
3. The method of claim 1 , wherein the fatty liver condition is nonalcoholic steatohepatitis (NASH).
4. The method of claim 3 , wherein the NASH score improves or decreases.
5. The method of claim 3 , wherein fasting serum triglyceride level decreases.
6. The method of claim 1 , wherein the fatty liver condition is nonalcoholic fatty liver disease (NAFLD).
7. A method of improving hepatitic steatosis in a non-lipodystrophic subject comprising administering a composition comprising leptin in an amount effective to improve hepatitic steatosis in the subject.
8. The method of claim 1 or 7 , wherein administering leptin decreases liver fibrosis or scarring in the subject.
9. The method of claim 1 or 7 , wherein administering leptin decreases liver inflammation in the subject.
10. The method of claim 1 or 7 , wherein administering leptin decreases liver fat in the subject.